Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2024.
Read more at globenewswire.com
